Medicine and Dentistry
Cetuximab
100%
Gefitinib
62%
Non Small Cell Lung Cancer
37%
Cancer Cell
25%
Cross Resistance
25%
Cycloheximide
25%
Signal Transduction
12%
Receptor
12%
Genetic Transfection
12%
Resistant Cell Line
12%
Tyrosine-Kinase Inhibitor
12%
Monoclonal Antibody
12%
Akt Signaling
12%
Protein Synthesis Inhibitor
12%
Phosphatidylinositol 3,4,5 Trisphosphate 3 Phosphatase
12%
EGFR Inhibitors
12%
Pharmacology, Toxicology and Pharmaceutical Science
Cetuximab
100%
Gefitinib
62%
Non Small Cell Lung Cancer
37%
Cycloheximide
25%
Cross-Resistance
25%
Protein Tyrosine Kinase Inhibitor
12%
Receptor
12%
Monoclonal Antibody
12%
Phosphatidylinositol 3,4,5 Trisphosphate 3 Phosphatase
12%
Protein Synthesis Inhibitor
12%
Agricultural and Biological Sciences
Cetuximab
100%
Cycloheximide
25%
Cross Resistance
25%
Resistance Mechanisms
25%
Proteins
12%
Cell Lines
12%
Receptors
12%
Tyrosine
12%
Transfection
12%
Protein Synthesis
12%
Monoclonal Antibody
12%
Chemistry
Gefitinib
100%
Cycloheximide
40%
Protein
20%
% Inhibition
20%
Tyrosine Kinase Inhibitor
20%
Protein Synthesis Inhibitor
20%